PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
A new study from the Italian Institute of Technology (IIT), in collaboration with Uppsala University (Sweden) and AstraZeneca ...
PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splici ...
Johns Hopkins researchers have developed a powerful new AI tool called Splam that can identify where splicing occurs in genes—an advance that could help scientists analyze genetic data with greater ...
A collaborative study published today in the journal Cell Reports provides evidence for a new molecular cause for neurodegeneration in Alzheimer’s disease. The study, led by researchers at Baylor ...
Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global ...
Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March ...
A wide spectrum of cancer-associated genetic alterations, including those that result in changes to the splicing of pre–messenger RNA (mRNA), can lead to the presentation of aberrant peptides as ...
Researchers developed molecules, called splice-switching oligonucleotides (SSOs) that bind to the RNA molecules encoding a protein known as REST. In neuroendocrine tumors, these RNAs are incorrectly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results